Publications by authors named "Jan Marsal"

Claim this Profile
M
Mesalamine for Colorectal Cancer Prevention Programme in Lynch syndrome (MesaCAPP): a multicentre, multinational, randomised, two-arm, double-blind, phase II clinical study with mesalamine or placebo in carriers with Lynch syndrome - a study protocol.
Ann-Sofie Backman, Alexander Frank, Lars Joachim Lindberg, David Ljungman, Gustav Silander, Jan Marsal

BMJ Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory Bowel Disease, Periconceptional Disease Activity, and Risk of Major Congenital Anomalies: A Nationwide Cohort Study.
Karl Mårild, Jonas Söderling, Olof Stephansson, Jordan Axelrad, Jonas Halfvarson, Jan Marsal

Am J Gastroenterol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis - report of two filgotinib-treated cases and literature review.
Henrik Ekedahl, Gudbjörg Sigurjonsdottir, Viktoria Bergqvist, Björn Båtshake, Ana Carneiro, Jan Marsal

Acta Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gut inflammation is associated with structural spinal damage in axial spondyloarthritis - results from the observational SPARTAKUS cohort.
Johan Karlsson Wallman, Elisabeth Mogard, Jonas Sagard, Kristofer Andréasson, Jan Marsal

Arthritis Res Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective observational study of tofacitinib in ulcerative colitis - analysis of clinical data, fatigue and health-related quality of life during the induction phase.
Lisa Nyberg, Jonas Halfvarson, Jonas Söderling, Ola Olén, Hans Strid, Jan Marsal

Therap Adv Gastroenterol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cohort profile: the Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD).
Benita Salomon, Olle Grännö, Daniel Bergemalm, Hans Strid, Adam Carstens, Jan Marsal

BMJ Open· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endoscopic scoring of immune-mediated colitis disease activity.
Viktoria Bergqvist, Peter Gedeon, Erik Hertervig, Jan Marsal

Gastrointest Endosc· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histologic Remission in Inflammatory Bowel Disease and Female Fertility: A Nationwide Study.
Karl Mårild, Jonas Söderling, Olof Stephansson, Jordan Axelrad, Jonas Halfvarson, Jan Marsal

Gastroenterology· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyaluronic Acid-Conjugated Thermoresponsive Polymer-Based Bioformulation Enhanced Wound Healing and Gut Barrier Repair of a TNBS-Induced Colitis Injury Ex Vivo Model in a Dynamic Perfusion Device.
Ayushi Mairal, Shreya Mehrotra, Anupam Kumar, Rakhi Maiwal, Jan Marsal

ACS Appl Mater Interfaces· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[New solutions for an old problem : Current developments in oral contrast agents].
Thomas Fork, Ingvar Adnerhill, Olof Böök, Lucia Casal-Dujat, Peter Leander, Jan Marsal

Radiologie (Heidelb)· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study.
Isabella Visuri, Carl Eriksson, Sara Karlqvist, Byron Lykiardopoulos, Per Karlén, Jan Marsal

Therap Adv Gastroenterol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alkaline sphingomyelinase (NPP7) impacts the homeostasis of intestinal T lymphocyte populations.
Manar Alyamani, Mohammad Kadivar, Jonas Erjefält, Bengt Johansson-Lindbom, Rui-Dong Duan, Jan Marsal

Front Immunol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergency subtotal colectomy rates in relation to anti-TNF therapy in inflammatory bowel disease patients: comparison of retrospective cohorts.
Saman Sajjadi, Rebecca Svensson Neufert, Emilia Ruhr, Sebastian Tryggmo, Jan Marsal

Scand J Gastroenterol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes: A nationwide study.
Karl Mårild, Jonas Söderling, Olof Stephansson, Jordan Axelrad, Jonas Halfvarson, Jan Marsal

EClinicalMedicine· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter: to switch or not to switch, that is the question-author's reply.
Viktoria Bergqvist, Johanna Holmgren, Daniel Klintman, Jan Marsal

Aliment Pharmacol Ther· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discontinuation of Infliximab Therapy in Patients with Crohn's Disease.
Sine Buhl, Casper Steenholdt, Jørn Brynskov, Katrine Risager Christensen, Maria Dorn-Rasmussen, Jan Marsal

NEJM Evid· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: intravenous to subcutaneous vedolizumab-switch without glitch! Authors' reply.
Viktoria Bergqvist, Johanna Holmgren, Daniel Klintman, Jan Marsal

Aliment Pharmacol Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.
Viktoria Bergqvist, Johanna Holmgren, Daniel Klintman, Jan Marsal

Aliment Pharmacol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.
Jan Marsal, Manuel Barreiro-de Acosta, Irina Blumenstein, Maria Cappello, Thomas Bazin

Front Med (Lausanne)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel food-based negative oral contrast agent compared with two conventional oral contrast agents in abdominal CT: a three-arm parallel blinded randomised controlled single-centre trial.
Peter Leander, Georgios Stathis, Lucia Casal-Dujat, Karolina Boman, Ingvar Adnerhill, Jan Marsal

Eur Radiol Exp· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis.
Jonas Sagard, Tor Olofsson, Elisabeth Mogard, Jan Marsal, Kristofer Andréasson

Arthritis Res Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study.
Carl Eriksson, Sara Rundquist, Vyron Lykiardopoulos, Ruzan Udumyan, Per Karlén, Jan Marsal

Therap Adv Gastroenterol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung Mast Cells Have a High Constitutive Expression of Carboxypeptidase A3 mRNA That Is Independent from Granule-Stored CPA3.
Premkumar Siddhuraj, Carl-Magnus Clausson, Caroline Sanden, Manar Alyamani, Mohammad Kadivar, Jan Marsal

Cells· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation-a prospective, observational study.
Kristofer Andréasson, Karl Neringer, Dirk M Wuttge, Dan Henrohn, Jan Marsal

Arthritis Res Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study.
Leif Angelison, Sven Almer, Loa Davidsdottir, Per Hammarlund, Stefan Lindgren, Jan Marsal

Scand J Gastroenterol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis